International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 79-84
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Prognostic Significance of Serum Matrix Metalloproteinase 9 (MMP-9) Levels in Patients with Sarcomas
Emel YAMAN1, Bülent YALÇIN2, Güngör UTKAN2, Hakan AKBULUT2, Abdurrahman IŞIKDOĞAN3, Orhan ŞENCAN2, Abdullah BÜYÜKÇELİK2, Ali PAMİR2, Ahmet DEMİRKAZIK2, Fikri IÇLİ2
1Gazi University Faculty of Medicine, Medical Oncology Department, ANKARA
2Ankara University Faculty of Medicine, Medical Oncology Department, ANKARA
3Dicle University Faculty of Medicine, Medical Oncology Department, DİYARBAKIR
Keywords: Serum MMP-9, Sarcoma
Sarcomas are heterogeneous groups of tumors that are seen rarely. Although great efforts have been made to identify prognostic factors apart from grade, histology and tumor size, they’re not so obvious yet. In this study, the prognostic role of serum matrix metalloproteinase (MMP)-9 levels in patients with sarcoma was evaluated.
Eighty-eight patients with a diagnosis of sarcoma were included in the study. Additionally in 14 patients with osteosarcoma, serum MMP-9 levels were analyzed twice, one in preoperative period during neoadjuvant chemotherapy and one in postoperative period. Sixteen healthy volunteers composed the control group. Serum MMP-9 levels have been evaluated quantitively by ELISA method.
Serum MMP-9 levels were higher significantly compared to control group (p<0.005). Patients with metastatic disease have higher serum MMP-9 levels compared to the non-metastatic ones which were statistically non-significant (p: 0.9). Similarly, no difference in serum MMP-9 levels was observed between patients with intermediate-high grade tumors and with low grade tumors. Moreover, statistically significant decrease in serum MMP-9 levels was observed in patients in postoperative period compared to preoperative period (p: 0.016).
Although this study was performed in small number and heterogeneous group of patients, the difference in serum MMP-9 levels between sarcoma patients and control group, especially in the presence of measurable lesions and in postoperative period of the same patients, suggests that serum MMP-9 levels may be used as a tumor marker in patients with sarcoma.
Emel YAMAN1, Bülent YALÇIN2, Güngör UTKAN2, Hakan AKBULUT2, Abdurrahman IŞIKDOĞAN3, Orhan ŞENCAN2, Abdullah BÜYÜKÇELİK2, Ali PAMİR2, Ahmet DEMİRKAZIK2, Fikri IÇLİ2
1Gazi University Faculty of Medicine, Medical Oncology Department, ANKARA
2Ankara University Faculty of Medicine, Medical Oncology Department, ANKARA
3Dicle University Faculty of Medicine, Medical Oncology Department, DİYARBAKIR
Keywords: Serum MMP-9, Sarcoma
Sarcomas are heterogeneous groups of tumors that are seen rarely. Although great efforts have been made to identify prognostic factors apart from grade, histology and tumor size, they’re not so obvious yet. In this study, the prognostic role of serum matrix metalloproteinase (MMP)-9 levels in patients with sarcoma was evaluated.
Eighty-eight patients with a diagnosis of sarcoma were included in the study. Additionally in 14 patients with osteosarcoma, serum MMP-9 levels were analyzed twice, one in preoperative period during neoadjuvant chemotherapy and one in postoperative period. Sixteen healthy volunteers composed the control group. Serum MMP-9 levels have been evaluated quantitively by ELISA method.
Serum MMP-9 levels were higher significantly compared to control group (p<0.005). Patients with metastatic disease have higher serum MMP-9 levels compared to the non-metastatic ones which were statistically non-significant (p: 0.9). Similarly, no difference in serum MMP-9 levels was observed between patients with intermediate-high grade tumors and with low grade tumors. Moreover, statistically significant decrease in serum MMP-9 levels was observed in patients in postoperative period compared to preoperative period (p: 0.016).
Although this study was performed in small number and heterogeneous group of patients, the difference in serum MMP-9 levels between sarcoma patients and control group, especially in the presence of measurable lesions and in postoperative period of the same patients, suggests that serum MMP-9 levels may be used as a tumor marker in patients with sarcoma.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |